#AAN2018 – PRIME Trial Data Show Long-term Benefits of Aducanumab in Early Alzheimer’s

#AAN2018 – PRIME Trial Data Show Long-term Benefits of Aducanumab in Early Alzheimer’s
Long-term use of BIIB037 (aducanumab) can prevent progression of Alzheimer’s in patients at early stages of the disease, according to results from the PRIME study. Biogen, maker of aducanumab, will present those results at the 2018 Annual Meeting of the American Academy of Neurology (AAN), April 21-27 in Los Angeles, California. The clinical effects of 24

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

6 comments

  1. Daniel R Bryson says:

    All of these clinical tests are run using only candidates with early detection of Alzheimers. Why aren’t any of the “trials” run on candidates, that have been patients for 3, 4 or 5 years and can not pass the written tests, to see if these clinical trials will give others some hope and optimism to them and their family. I have repeatedly asked and asked if there is a place/research center running these trials and I get no help! Have the researchers, investors and government given up on all of these candidates. Wouldn’t it make sense if a person that has advanced dementia had favorable reaction to one of these drugs that it would indicate the possibilities of IT being a start towards the cure??? Will travel to participate in one of these trials!

    • Jeff. Rader says:

      To: Dan Bryson, You would need a referral from your primary care physician to go. You can try Department of Neurology Memory Disorders Clinic Ohio State University in Columbus, Ohio 43210, Phone: 614-293-4969.

    • Sonia Tarantino says:

      I agree that these memorie tests exclude some good candidates for studies that could benefit from these trials.

  2. DANTE MARCIANI says:

    The results of aducanumab are a good proof that a preventive AD vaccine intelligently designed would be an effective way to prevent or delay the onset of AD. I said “intelligently” because all the past vaccines were designed to fail, but with the hope that they will work. Because of the neurodegenerative nature of AD, it is near to impossible to honestly talk about a cure for advanced cases. Yet, preventing or delaying the onset of AD, would be welcomed news for society.

  3. PTM says:

    When is old, too old to yield important results in the trials? I am the guardian of a 94 year old. She practiced child psychotherapy into her 90s. When dementia hit her, she was 91 years old and was still practicing part-time. Dementia hit her fast and hard, yet she retained her intelligence–just not her memory. She still has fairly accurate reasoning, can follow conversations, even discusses psychology theory and solves some of the problems of her nurses. She just can’t remember if she ate, how to get dressed and what she talked about five minutes after a conversation ends. She is physically healthy and could still have many years left (relatively speaking). I would love information on the trials and if even, at her advanced age and stage of dementia if she might not be a candidate who could yield some valuable information in the drug trials. The real Dr. B would love being part of a breakthrough of this kind.

  4. james says:

    The Biogen company announced in Feb/2018 the current BIIB037 (aducanumab)phase 3 result was not expected as their original assumption based on phase 2 result. The company added 500 more sample size patients and expect the result in 2020.

    It is confusing to see here to have the breakthrough in less 2 months to have this conference in April ?

    https://www.bloomberg.com/news/articles/2018-02-14/biogen-drops-after-alzheimer-s-drug-trial-change-raises-concerns

Leave a Comment

Your email address will not be published. Required fields are marked *